Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-05. Numbers and descriptions here follow the published literature rather than marketing material.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
==== Structure ==== The extracellular domains serve as the ligand-binding part of the molecule, often inducing the domains to form homo- or heterodimers. The transmembrane element is a single α helix. The intracellular or cytoplasmic Protein kinase domain is responsible for the (highly conserved) kinase activity, as well as several regulatory functions.
extraction with an extraction solution, usually NaOH column filtration using a macroporous adsorption resin a rinse with ethanol to remove impurities, and finally freeze the product to isolate the lawsone powder, usually a yellow colored dust. During the rinse, the lawsone will be the bottom as it has such a high density and the chlorophyll molecules will all be on the top of the mixture. Lawsone is hypothesized to undergo a reaction similar to Strecker synthesis in reactions with amino acids. Recent research has been conducted on lawsone's potential applications in the forensic science field. Since lawsone shows many similarities with ninhydrin, the current reagent for latent fingerprint development, studies have been conducted to see if lawsone can be used in this field. As of now the research is inconclusive, but optimistic. Lawsone non-specifically targets primary amino acids, and displays photoluminescence with forensic light sources. It has a characteristic purple/brown coloration as opposed to the purple/blue associated with ninhydrin. Lawsone shows promise as a reagent for fingerprint detection because of its photoluminescence maximized at 640 nm, which is high enough that it avoids background interference common for ninhydrin.
The Mazda MX-5 was developed around the same time in the US, but had tried to imitate the 1960s Lotus Elan. How Naoki Sakai originated the Italian-heritage Nissan Figaro in the early 1990s - the car, made for Japanese women in a limited production, became so popular that it had to be sold by lottery. How the Mazda research centre at Kanagawa-ku, Yokohama was making intelligent cars.
“A New Pentacyclic Pyrylium Fluorescent Probe that Responds to pH Imbalance During Apoptosis”. Chem. Sci., 2020,11, 12695-12700. https://doi.org/10.1039/D0SC02623A. A. Mal, S. Vijayakumar, R. K. Mishra, J. Jacob, R. S. Pillai, B. S. Dileep Kumar and Ajayaghosh, Ayyappanpillai (2020). “Supramolecular Surface Charge Regulation in Ionic Covalent Organic Nanosheets for Reversible Exfoliation and Controlled Bacterial Growth”. Angew. Chem., Int. Ed. 2020, 59, 8713-8719. https://doi.org/10.1002/anie.201912363. G, Das.; S, Cherumukkil.; A, Padmakumar.; V, B, Banakar.; V, K, Praveen.; and Ajayaghosh, Ayyappanpillai (2021). “Tweaking a BODIPY Spherical Self-Assembly to 2D Supramolecular Polymers Facilitates Excited State Cascade Energy Transfer”. Angew. Chem. Int. Ed. 2021, 60, 7851-7938. https://doi.org/10.1002/ange.202015390. A, Nirmala.; I, Mukkatt.; S, Shankar.; and Ajayaghosh, Ayyappanpillai (2021). “Thermochromic Color Switching to Temperature Controlled Volatile Memory and Counter Operations with Metal-Organic Complexes and Hybrid Gels”. Angew. Chem., Int. Ed. 2021, 60, 455-465. https://doi.org/10.1002/anie.202011580. I, Mukkatt.; A, P, Mohanachandran.; A, Nirmala.; D, Patra.; P, A, Sukumaran.; R, S, Pillai.; R, B, Rakhi.; S, Shankar.; and Ajayaghosh, Ayyappanpillai (2022). “Tunable Capacitive Behavior in Metallopolymer-based Electrochromic Thin Film Supercapacitors”. ACS Appl. Mater. Interfaces, 2022, 14, 31900-31910. https://doi.org/10.1021/acsami.2c05744
Sources: en.wikipedia.org
As he further noted, China "has a much more developed manufacturing base than the old Soviet Union", making a Second Cold War "potentially more dangerous than the" original Cold War, and China's manufacturing capabilities have surpassed those of the US, which "has allowed its industrial base to be hollowed out over the years while supply chains splintered and moved overseas".
== Dye colour == The suffix "R" in the name of Coomassie brilliant blue R-250 is an abbreviation for "red" as the blue colour of the dye has a slight reddish tint. For the "G" variant the blue colour has a more greenish tint. The "250" originally denoted the purity of the dye. The colour of the two dyes depends on the acidity of the solution. The "G" form of the dye has been studied in detail. At a pH of less than 0 the dye has a red colour with an absorption maximum at a wavelength of 465 nm. At a pH of around 1 the dye is green with an absorption maximum at 620 nm while above pH 2 the dye is bright blue with a maximum at 595 nm. At pH 7 the dye has an extinction coefficient of 43,000 M−1 cm−1. The different colours are a result of the different charged states of the dye molecule. In the red form, all three nitrogen atoms carry a positive charge. The two sulfonic acid groups have extremely low pKa and will normally be negatively charged, thus at a pH of around zero the dye will be a cation with an overall charge of +1. The green colour corresponds to a form of the dye with no net overall charge. In neutral media (pH 7), only the nitrogen atom of the diphenylamine moiety carries a positive charge and the blue dye molecule is an anion with an overall charge of −1. The pKa values for the losses of the two protons are 1.15 and 1.82, respectively. The final proton is lost under alkaline conditions and the dye becomes pink (pKa 12.4). The dye interacts electrostatically but noncovalently with the amino and carboxyl groups of proteins.
Polymer–polymer systems. In a Polymer–polymer system, both phases are generated by a dissolved polymer. The heavy phase will generally be a polysaccharide, and the light phase is generally Polyethylene glycol (PEG). Traditionally, the polysaccharide used is dextran. However, dextran is relatively expensive, and research has been exploring using less expensive polysaccharides to generate the heavy phase. If the target compound being separated is a protein or enzyme, it is possible to incorporate a ligand to the target into one of the polymer phases. This improves the target's affinity to that phase, and improves its ability to partition from one phase into the other. This, as well as the absence of solvents or other denaturing agents, makes polymer–polymer extractions an attractive option for purifying proteins. The two phases of a polymer–polymer system often have very similar densities, and very low surface tension between them. Because of this, demixing a polymer–polymer system is often much more difficult than demixing a solvent extraction. Methods to improve the demixing include centrifugation, and application of an electric field. Polymer–salt systems. Aqueous two-phase systems can also be generated by generating the heavy phase with a concentrated salt solution. The polymer phase used is generally still PEG. Generally, a kosmotropic salt, such as Na3PO4 is used, however PEG–NaCl systems have been documented when the salt concentration is high enough. Since polymer–salt systems demix readily they are easier to use.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.